Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab

[1]  J. Curtis,et al.  Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease , 2020, American journal of respiratory and critical care medicine.

[2]  W. Busse,et al.  Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma , 2019, The Journal of asthma : official journal of the Association for the Care of Asthma.

[3]  W. Busse,et al.  Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma , 2019, Journal of asthma and allergy.

[4]  R. Katial,et al.  P221 BENRALIZUMAB TREATMENT IS NOT ASSOCIATED WITH ORAL CORTICOSTEROID–LIKE INCREASES IN WEIGHT AND BLOOD PRESSURE , 2019, Annals of Allergy, Asthma & Immunology.

[5]  M. Cabana,et al.  Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline , 2019, European Respiratory Journal.

[6]  E. Jacobsen,et al.  2094-P: Decreased Human Adipose Tissue-Resident Eosinophils in Obese Subjects Is Associated with Increased Insulin Resistance , 2019, Diabetes.

[7]  V. Backer,et al.  Benralizumab for the Prevention of COPD Exacerbations. , 2019, The New England journal of medicine.

[8]  N. Hanania,et al.  Targeting IL-5 in COPD , 2019, International journal of chronic obstructive pulmonary disease.

[9]  P. Colarusso,et al.  Intravital imaging allows real-time characterization of tissue resident eosinophils , 2019, Communications Biology.

[10]  F. Albers,et al.  Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis , 2019, Respiratory Research.

[11]  H. Ortega,et al.  Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma , 2019, The Journal of allergy and clinical immunology.

[12]  M. Fay,et al.  Benralizumab for PDGFRA‐Negative Hypereosinophilic Syndrome , 2019, The New England journal of medicine.

[13]  Meilan K. Han,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 , 2019, European Respiratory Journal.

[14]  A. Mishra,et al.  Disseminated herpes zoster following treatment with benralizumab , 2019, The clinical respiratory journal.

[15]  James J. Lee,et al.  Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer , 2019, Cancer Immunology Research.

[16]  H. Makita,et al.  Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. , 2019, The Lancet. Respiratory medicine.

[17]  Bora study investigators.  Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial , 2019 .

[18]  M. Sadatsafavi,et al.  A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma , 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.

[19]  Zhibo B. Xu,et al.  Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis , 2018, Infection.

[20]  P. Zeitlin,et al.  Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial , 2018, Journal of asthma and allergy.

[21]  A. Peters,et al.  Mepolizumab use: Post-approval academic practice experience. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[22]  F. Roufosse.  Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma , 2018, Front. Med..

[23]  G. Marone,et al.  Eosinophils: The unsung heroes in cancer? , 2018, Oncoimmunology.

[24]  L. Dagna,et al.  Eosinophils from Physiology to Disease: A Comprehensive Review , 2018, BioMed research international.

[25]  A. White,et al.  Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. , 2017, Clinical therapeutics.

[26]  J. Fahrenholz,et al.  Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. , 2017, The journal of allergy and clinical immunology. In practice.

[27]  R. Savino,et al.  Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab , 2017, Drug design, development and therapy.

[28]  G. Canonica,et al.  Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma , 2017, Front. Med..

[29]  C. Perronne,et al.  Changes in eosinophil count during bacterial infection: revisiting an old marker to assess the efficacy of antimicrobial therapy. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[30]  T. Marichal,et al.  Homeostatic Eosinophils: Characteristics and Functions , 2017, Front. Med..

[31]  M. Johansson.  Eosinophil Activation Status in Separate Compartments and Association with Asthma , 2017, Front. Med..

[32]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[33]  P. Thomas,et al.  Eosinophils Promote Antiviral Immunity in Mice Infected with Influenza A Virus , 2017, The Journal of Immunology.

[34]  A. Vanasse,et al.  Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions , 2017, Chest.

[35]  Jun Liu,et al.  Asthma and the risk of lung cancer: a meta-analysis , 2017, Oncotarget.

[36]  M. Karin,et al.  Targeting Inflammation in Cancer Prevention and Therapy , 2016, Cancer Prevention Research.

[37]  A. Munitz,et al.  Emerging Roles for Eosinophils in the Tumor Microenvironment. , 2016, Trends in cancer.

[38]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[39]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[40]  J. Appleton,et al.  Eosinophils in Helminth Infection: Defenders and Dupes. , 2016, Trends in parasitology.

[41]  M. Thiry,et al.  Lung-resident eosinophils represent a distinct regulatory eosinophil subset. , 2016, The Journal of clinical investigation.

[42]  D. Price,et al.  Historical cohort study examining comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease , 2016, Journal of asthma and allergy.

[43]  Christopher E Brightling,et al.  Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. , 2016, The Lancet. Respiratory medicine.

[44]  K. Ranade,et al.  Reductions in eosinophil biomarkers by benralizumab in patients with asthma. , 2016, Respiratory Medicine.

[45]  V. Apostolopoulos,et al.  Eosinophils in Cancer: Favourable or Unfavourable? , 2016, Current medicinal chemistry.

[46]  David Price,et al.  Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice , 2016, Journal of asthma and allergy.

[47]  K. Ravin,et al.  The Eosinophil in Infection , 2016, Clinical Reviews in Allergy & Immunology.

[48]  Mike Thomas,et al.  Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. , 2015, The Lancet. Respiratory medicine.

[49]  J. Mei,et al.  The infiltration and functional regulation of eosinophils induced by TSLP promote the proliferation of cervical cancer cell. , 2015, Cancer letters.

[50]  Nobhojit Roy,et al.  The Global Burden of Cancer 2013. , 2015, JAMA oncology.

[51]  B. Zhou,et al.  Inflammation fuels tumor progress and metastasis. , 2015, Current pharmaceutical design.

[52]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[53]  B. Fingleton,et al.  Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. , 2015, Cancer research.

[54]  P. Paggiaro,et al.  Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study , 2015, BMJ Open.

[55]  Eh Lee,et al.  IL-1β in eosinophil-mediated small intestinal homeostasis and IgA production , 2014, Mucosal Immunology.

[56]  R. Sehmi,et al.  Anti-IL5 therapy for asthma and beyond , 2014, The World Allergy Organization journal.

[57]  Dave Singh,et al.  Eosinophilic inflammation in COPD: prevalence and clinical characteristics , 2014, European Respiratory Journal.

[58]  P. Kantoff,et al.  A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T , 2014, Cancer Immunology Research.

[59]  K. Rothman,et al.  Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. , 2014, The Journal of allergy and clinical immunology.

[60]  Y. Juhn.  Risks for infection in patients with asthma (or other atopic conditions): is asthma more than a chronic airway disease? , 2014, The Journal of allergy and clinical immunology.

[61]  W. Busse,et al.  Asthma and infections: is the risk more profound than previously thought? , 2014, The Journal of allergy and clinical immunology.

[62]  R. Palmiter,et al.  Eosinophils and Type 2 Cytokine Signaling in Macrophages Orchestrate Development of Functional Beige Fat , 2014, Cell.

[63]  Ronald E Gangnon,et al.  Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations. , 2014, The Journal of allergy and clinical immunology.

[64]  C. Berek,et al.  Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. , 2014, Immunity.

[65]  Megha Jain,et al.  Assessment of Tissue Eosinophilia as a Prognosticator in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma—An Image Analysis Study , 2014, Pathology research international.

[66]  R. Louis,et al.  Importance of concomitant local and systemic eosinophilia in uncontrolled asthma , 2014, European Respiratory Journal.

[67]  James J. Lee,et al.  Activated mouse eosinophils protect against lethal respiratory virus infection. , 2014, Blood.

[68]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[69]  W. Busse,et al.  Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. , 2013, The Journal of allergy and clinical immunology.

[70]  B. Yawn,et al.  Increased risk of herpes zoster in children with asthma: a population-based case-control study. , 2013, The Journal of pediatrics.

[71]  H. Kita,et al.  Induction of Malignant Plasma Cell Proliferation by Eosinophils , 2013, PloS one.

[72]  James J. Lee,et al.  The consequences of not having eosinophils , 2013, Allergy.

[73]  J. Sheikh,et al.  Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. , 2013, The Journal of allergy and clinical immunology.

[74]  Y. Juhn,et al.  Increased risk of pertussis in patients with asthma. , 2012, The Journal of allergy and clinical immunology.

[75]  Y. Juhn,et al.  Streptococcus pyogenes upper respiratory infection and atopic conditions other than asthma: a retrospective cohort study. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

[76]  K. Tsuneyama,et al.  Identification of Innate IL-5–Producing Cells and Their Role in Lung Eosinophil Regulation and Antitumor Immunity , 2012, The Journal of Immunology.

[77]  K. Takatsu.  Interleukin-5 and IL-5 receptor in health and diseases , 2011, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[78]  J. Slim,et al.  Eosinopenia: Is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital? , 2010, Journal of critical care.

[79]  B. Fingleton,et al.  Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. , 2010, American journal of respiratory and critical care medicine.

[80]  S. Babayan,et al.  Filarial Parasites Develop Faster and Reproduce Earlier in Response to Host Immune Effectors That Determine Filarial Life Expectancy , 2010, PLoS biology.

[81]  C. Roussos,et al.  Allergic inflammation does not impact chemical-induced carcinogenesis in the lungs of mice , 2010, Respiratory research.

[82]  C. Mackay,et al.  MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. , 2010, The Journal of allergy and clinical immunology.

[83]  James J. Lee,et al.  Eosinophils in health and disease: the LIAR hypothesis , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[84]  P. Weller,et al.  Eosinophils as antigen-presenting cells in allergic upper airway disease , 2010, Current opinion in allergy and clinical immunology.

[85]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[86]  James J. Lee,et al.  Eosinophil Deficiency Compromises Parasite Survival in Chronic Nematode Infection1 , 2009, The Journal of Immunology.

[87]  Z. Nemes,et al.  Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin’s lymphoma , 2008, Pathology & Oncology Research.

[88]  S. Wenzel,et al.  Tissue and BAL based biomarkers in asthma. , 2007, Immunology and allergy clinics of North America.

[89]  S. Phipps,et al.  Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. , 2007, Blood.

[90]  I. Pavord,et al.  Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial , 2007, European Respiratory Journal.

[91]  Marc E. Rothenberg,et al.  Regulation of Carcinogenesis by IL-5 and CCL11: A Potential Role for Eosinophils in Tumor Immune Surveillance1 , 2007, The Journal of Immunology.

[92]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON CONDUCT OF PHARMACOVIGILANCE FOR MEDICINES USED BY THE PAEDIATRIC POPULATION , 2007 .

[93]  Xiaomei Ma,et al.  Global Burden of Cancer , 2006, The Yale journal of biology and medicine.

[94]  James J. Lee,et al.  Eosinophils Can Function as Antigen-Presenting Cells To Induce Primary and Secondary Immune Responses to Strongyloides stercoralis , 2006, Infection and Immunity.

[95]  L. G. García Rodríguez,et al.  Cancer incidence in a general population of asthma patients , 2006, Pharmacoepidemiology and drug safety.

[96]  M. Thun,et al.  Cancer mortality among US men and women with asthma and hay fever. , 2005, American journal of epidemiology.

[97]  C. Wennerås,et al.  Human eosinophils selectively recognize and become activated by bacteria belonging to different taxonomic groups. , 2005, Microbes and infection.

[98]  S. Orkin,et al.  A Critical Role for Eosinophils in Allergic Airways Remodeling , 2004, Science.

[99]  E. Lenkiewicz,et al.  Defining a Link with Asthma in Mice Congenitally Deficient in Eosinophils , 2004, Science.

[100]  D. Molin.  Bystander Cells and Prognosis in Hodgkin Lymphoma , 2004 .

[101]  D. Molin.  Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis. , 2004, Upsala journal of medical sciences.

[102]  P. Foster,et al.  Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells , 2003, The Journal of experimental medicine.

[103]  A. Kay,et al.  Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.

[104]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[105]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[106]  S. Orkin,et al.  Targeted Deletion of a High-Affinity GATA-binding Site in the GATA-1 Promoter Leads to Selective Loss of the Eosinophil Lineage In Vivo , 2002, The Journal of experimental medicine.

[107]  K. Kameyama,et al.  Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. , 2002, Auris, nasus, larynx.

[108]  P. Boffetta,et al.  Lung cancer risk in a population-based cohort of patients hospitalized for asthma in Sweden , 2002, European Respiratory Journal.

[109]  H. Nielsen,et al.  Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue , 1999, The Journal of pathology.

[110]  H. Rosenberg,et al.  Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. , 1999, American journal of respiratory and critical care medicine.

[111]  S. Rankin,et al.  Mechanisms of Acute Eosinophil Mobilization from the Bone Marrow Stimulated by Interleukin 5: The Role of Specific Adhesion Molecules and Phosphatidylinositol 3-Kinase , 1998, The Journal of experimental medicine.

[112]  N. Talley,et al.  Eosinophil infiltration and degranulation in normal human tissue , 1998, The Anatomical record.

[113]  K. Dyer,et al.  Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. , 1998, Nucleic acids research.

[114]  T. Blankenstein,et al.  Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. , 1998, Journal of immunology.

[115]  M. Samoszuk.  Eosinophils and human cancer. , 1997, Histology and histopathology.

[116]  A. Zwinderman,et al.  Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response. , 1996, Human pathology.

[117]  L. Fabbri,et al.  Airway eosinophilia in chronic bronchitis during exacerbations. , 1994, American journal of respiratory and critical care medicine.

[118]  E. Pukkala,et al.  Cancer incidence among 78,000 asthmatic patients. , 1993, International journal of epidemiology.

[119]  T. Blankenstein,et al.  Eosinophils infiltrating interleukin‐5 gene‐transfected tumors do not suppress tumor growth , 1993, European journal of immunology.

[120]  D. Jones.  The eosinophil. , 1993, Journal of comparative pathology.

[121]  H. Rockette,et al.  Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). , 1989, Human pathology.

[122]  E. Goetzl,et al.  Circulating eosinophil colony-forming cells in pure eosinophil aplasia. , 1984, Annals of internal medicine.

[123]  R. Wever,et al.  The killing of newborn larvae of Trichinella spiralis by eosinophil peroxidase in vitro , 1981, European journal of immunology.

[124]  A. Capron,et al.  In vitro killing of S. mansoni schistosomula by eosinophils from infected rats: role of cytophilic antibodies. , 1979, Journal of immunology.

[125]  W. Lipkin.  Eosinophil counts in bacteremia. , 1979, Archives of Internal Medicine.

[126]  D. A. Bass.  Behavior of eosinophil leukocytes in acute inflammation. II. Eosinophil dynamics during acute inflammation. , 1975, The Journal of clinical investigation.

[127]  S. Krantz,et al.  Studies on red cell aplasia. I. Demonstration of a plasma inhibitor to heme synthesis and an antibody to erythroblast nuclei. , 1967, Proceedings of the National Academy of Sciences of the United States of America.